Navigation Links
The Best Radiation Therapy Solution just got Better
Date:7/18/2012

SUNNYVALE, Calif., July 18, 2012 /PRNewswire/ -- IntraOp Medical Corporation (OTC: IOPD.PK - News) installed the 10th of the next generation Mobetrons last week at Helios-Kliniken (helios-kliniken.de) in Berlin Germany.  The Mobetron is used for electron IORT (IOERT), which has demonstrated the best overall clinical results of any breast cancer treatment, resulting in 10 year recurrence rates as low as 1%.  Currently each Mobetron in Germany treats between 250-350 breast cancer patients per year with IOERT. Many of these patients are also eligible for oncoplastic reconstruction which eliminates the need for additional cosmetic surgery and speeds the process of "emotional reconstruction".  Germany is a leader of evidence based medicine.  The rapid adoption of IOERT for breast cancer treatment is immediately allowing thousands of women with breast cancer to achieve better results and cosmesis, over a shorter treatment course.  IOERT provides the treatment flexibility to accommodate nearly all breast patients including younger pre-menopausal patients.

"IOERT is becoming the gold standard in the successful treatment of cancer," says Ernesto G. Lanzotti, Director of MD51 Germany GmbH, IntraOp Medical European distributor.  "We are very proud to start cooperating with Helios Kliniken because we understand the importance from both a treatment and medical science aspect and Helios-Kliniken is a leader in this regard."

The next generation Mobetron has also added a new benefit to the environment as well.  The Mobetron provides radiation therapy (RT) more efficiently than any other RT technique, using less time, less energy, and producing little to no waste.  The Mobetron can deliver a complete course of radiation therapy for select breast cancer candidates in 2 minutes using less than one tenth of a kilowatt hour (kWh) of electricity.  The same treatment using conventional external beam radiation therapy requires 90 minutes of treatment (beam) over 30 days and uses over 100 kWh's for treatment and cooling.

The Mobetron is a true linear accelerator and generates only the radiation it needs for a given treatment without having to use active radioactive radiation sources.  The Mobetron does not use disposable applicators like some of the other methods to treat cancers Intra-Operatively.  This is effective for reducing both cost and waste.  The Healthcare industry is the second largest producer of waste behind the food service industry and this will continue to be an area of great attention.  "Eventually, policy will be enacted to discourage waste as seen in other industries, and we want to help lead this initiative," said John Powers, IntraOp Medical's CEO.  For these reasons it is no surprise that the Mobetron is gaining more attention worldwide with Mobetrons recently shipping to new markets in Saudi Arabia and Turkey.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms and has been used to treat over 20 different cancer indications. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and happier patients with fewer side effects. Leading hospitals and clinics throughout the world use the Mobetron as a vital part of their comprehensive cancer program. For more information email info@intraopmedical.com or call 408-636-1020 x128.

About Helios

The HELIOS Hospital Group ranks among the largest and most medically advanced hospital groups in Germany. Since 2005 HELIOS is part of the global healthcare provider Fresenius Fresenius SE & Co.KGaA.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.


'/>"/>
SOURCE IntraOp Medical Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Radiation Therapy in Oncology Drug Pipeline Update 2012
2. Elektas Gamma Knife and Radiation Therapy Systems for Cancer Treatment Take Top Three Places in 2012s Best in KLAS for Radiation Therapy
3. ViewRay Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System
4. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
5. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
6. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
7. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
8. Largest Public Hospital in Sydney Delivers First Treatment in Australia Using Advanced TrueBeam Radiotherapy and Radiosurgery Device
9. United States Market for Psoriatic Arthritis Pharmacotherapy
10. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
11. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , and GAITHERSBURG, Md. , Jan. ... XON ), a leader in the engineering and industrialization of ... the planet, today announced that it has entered into a ... GNVC ), a clinical-stage company and pioneer in the ... intends to integrate and expand upon GenVec,s expertise in adenoviral ...
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... Research, titled, "Acidity Regulators Market - Global Opportunity Analysis ... regulators was valued at $4,456 million in 2015, and is expected ... 7.96% from 2016 to 2022. Asia-Pacific generated ... lead, followed by North America and ...
(Date:1/24/2017)... SEOUL, Korea , Jan. 24, 2017 ... Reddy,s in New Jersey State court alleging that Dr. ... deficiencies in its Food and Drug Administration (FDA) cGMP ... notes that Dr. Reddy,s repeatedly represented to Mezzion that ... hid its misconduct from Mezzion.  The suit also states ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... detect, and eliminate cyber threats in real-time, today announced a strategic partnership with ... enable customers to monitor, respond and protect their critical information assets and infrastructure, ...
(Date:1/24/2017)... ... 24, 2017 , ... Center for Hispanic Leadership (CHL) Academy , the ... Chavez, Manager, Employee & Labor Relations at City of Hope , a world-renowned ... the Month. City of Hope is committed to stay out in front of its ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the American Cancer ... good news for prostate cancer patients: incidents of cancer is down as is the ... the cancer death rate has dropped from its peak of 215.1 in 1991 to ...
(Date:1/24/2017)... ... 2017 , ... A yellow fever outbreak in Brazil has infected over 100 ... primarily spread through contact with infected mosquitos. The outbreak has sparked increased concern about ... , According to multiple health organizations, the best way to prevent yellow fever is ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... to improve the connection with God. “Spiritual Vitamins: A Spiritual Energy Booster” is ... by Christian Faith Publishing, Mathai Yohannan’s new book engages the mind and spirit ...
Breaking Medicine News(10 mins):